In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Effects of statins on inflammatory markers and matrix metalloproteinases in patients with ST-segment elevation myocardial infarction

Session Poster Session V - Saturday 08:30 -12:30

Speaker Tamara Pecherina

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Lipids
  • Session type : Poster Session

Authors : T Pecherina (Kemerovo,RU), V Kashtalap (Kemerovo,RU), O Barbarash (Kemerovo,RU)

Authors:
T Pecherina1 , V Kashtalap1 , O Barbarash1 , 1Research Institute for Complex Issues of Cardiov. Dis. - Siberian Branch RAMS Institution Scientific - Kemerovo - Russian Federation ,

On behalf: Pecherina T.B., Kashtalap V.V., Barbarash O.L.

Citation:

Aim: To evaluate the effects of statins on inflammatory markers and MMP-1, MMP-3, and MMP-9 in patients with ST-segment elevation myocardial infarction.
Materials and Methods: A prospective cohort study was conducted with 175 consecutive patients with STEMI. The mean age of all patients was 61.3 ± 8.4 years, of whom 116 (66.3%) were males and 59 (33.7%) were females. Serum concentrations of interleukin (IL-6, IL-10, IL-12), CRP, TNF-a and MMP-1, MMP-3, MMP-9 and blood lipid parameters were measured in all patients on days 1 and 12 of the onset of MI. All patients were enrolled into two groups: Group 1 (n=136 (77.71%) without statin therapy and Group 2 (n=39 (22.29%) with pre-hospital statin therapy. 
Results: Patients (n = 39) with statin use of at least 7 days prior to the onset of STEMI demonstrated significantly lower levels of LDL [2.91 (1.31; 5.13) vs 1.34 (0.76; 9.77]), compared to patients without statin therapy. However, there were no significant differences in the levels of total cholesterol, HDL and TG in both groups. After analyzing levels of studied biomarkers in both groups, significantly lower levels of inflammatory markers (IL-6, CRP, TNF-a), and MMP-9 on days 1 and 12 of STEMI in patients with pre-hospital statin therapy were found. There was a 2-fold increase of anti-inflammatory marker IL-10 in patients with pre-hospital statins, compared to patients without statins (Table 1).
Conclusion: Pre-hospital statin therapy in patients STEMI is associated with lower levels of proinflammatory markers (IL-6, CRP, TNF-a), and MMP-9 in the in-hospital period.

parameters

pre-hospital statin therapy

n=39 (22,29%)

without pre-hospital statin therapy

n=136 (77,71%)

?

day 1

day 12

day 1

day 12

1

2

3

4

TNF-α, pg /ml

0.98

(0.62; 2.68)

1.22

(0.64; 3.36)

1.76

(0.61; 2.8)

2.15

(0.85; 3.32)

?1.3=0.002

?2.4=0.008

IL-10 pg / ml

1.8

(0.51; 3.98)

1.42

(0.28; 2.67)

0.9

(0.2; 10.6)

0.7

(0.1; 4.4)

?1.3=0.0001

?2.4=0.0001

IL-6 pg / ml

18.09

(2.46; 47.3)

11.56

(2.77; 46.8)

12.4

(0.65; 73.8)

4.1

(0.1; 115.0)

?1.3=0.002

?2.4=0.0001

IL-12 pg / ml

56.34

(17.7; 196.6)

124.0

(38.18; 473.9)

98.5

(9.8; 994.0)

134.75

(24.98; 1068.0)

?1.3=0.01

?2.4>0.05

CRP, ??/?

20.0

(0.56; 95.0)

6.0

(2.26; 100.0)

26.44

(0.93; 54.97)

12.91

(1.3; 92.0)

?>0.05

MMP-1, pg / ml

1.08

(0.3; 6.9)

2.2

(0.21; 12.06)

1.58

(0.28; 19.54)

2.6

(0.22; 24.0)

?>0.05

MMP-3, pg / ml

14.65

(5.5; 54.2)

17.75

(4.7; 53.4)

15.02

(1.18; 86.88)

17.2

(3.8; 208.3)

?>0.05

MMP-9, pg / ml

120.0

(1.81; 1868.0)

93.6

(47.2; 191.0)

136.62

(25.0; 296.0)

115.7

(14.16; 1496.0)

?1.3=0.03

?2.4=0.01

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are